Short summary: GLP-1 receptor agonists are best known for blood sugar and weight effects, but kidney evidence is growing. The strongest kidney-outcome evidence is for semaglutide in adults with type 2 diabetes and chronic kidney disease studied in the FLOW trial.
Key takeaways
- The FLOW trial tested once-weekly semaglutide 1.0 mg in adults with type 2 diabetes and chronic kidney disease.
- Semaglutide lowered the relative risk of a composite outcome that included kidney failure, a sustained major decline in kidney function, kidney-related death, or cardiovascular death.
- This does not mean every GLP-1 medicine has the same kidney indication or that GLP-1 medicines replace SGLT2 inhibitors, ACE inhibitors, ARBs, or finerenone when those are appropriate.
- Kidney treatment should be individualized by eGFR, urine albumin, heart risk, side effects, cost, access, and other medicines.
What changed in the evidence
Earlier GLP-1 studies suggested kidney benefits, often through secondary outcomes such as less albumin in the urine. FLOW was different because it was designed to test kidney outcomes directly in people with type 2 diabetes and chronic kidney disease.
In FLOW, semaglutide was compared with placebo. The primary outcome combined kidney failure, a sustained decline of 50 percent or more in kidney function, kidney-related death, or cardiovascular death. The semaglutide group had a 24 percent lower relative risk of that combined outcome.
Why this matters
Chronic kidney disease is common in type 2 diabetes and often progresses quietly. Many people feel well until kidney function has already fallen. Treatments that reduce kidney and cardiovascular risk can matter because kidney disease and heart disease often travel together.
The ADA 2026 standards continue to emphasize a layered approach: blood pressure control, glucose management, kidney-protective medicines when indicated, cholesterol care, smoking cessation, nutrition, and regular monitoring of eGFR and urine albumin.
What GLP-1 medicines can and cannot promise
GLP-1 medicines can lower blood sugar and may reduce weight. Some also have cardiovascular outcome evidence. For kidney protection, the strongest current claim should stay specific: semaglutide has dedicated kidney-outcome trial evidence in adults with type 2 diabetes and chronic kidney disease.
It would be misleading to say all GLP-1 medicines protect the kidneys equally. It would also be misleading to treat GLP-1 therapy as a replacement for other kidney-protective care. Many patients need more than one risk-reduction strategy, and some cannot use certain medicines because of side effects, kidney function, pregnancy, gastrointestinal disease, pancreatitis history, cost, or access.
Questions to ask your care team
- What are my most recent eGFR and urine albumin results?
- Do I already qualify for an SGLT2 inhibitor, ACE inhibitor, ARB, finerenone, or GLP-1 medicine?
- Which treatment is most important for my kidney and heart risk right now?
- What side effects should I watch for, and when should I call?
Readers comparing kidney-protective medicines may also want our guides to SGLT2 inhibitors for kidney protection, finerenone for kidney and heart protection, and managing GLP-1 side effects.
Practical takeaway
If you have type 2 diabetes, ask whether your kidney risk has been checked with both eGFR and urine albumin. GLP-1 medicines may be part of kidney and heart risk care for selected people, but the decision should be based on your results, other medicines, benefits, side effects, and access.
Sources
- New England Journal of Medicine: FLOW trial of semaglutide in type 2 diabetes and chronic kidney disease
- American Diabetes Association: Chronic Kidney Disease and Risk Management, Standards of Care 2026
- American Diabetes Association: Pharmacologic Approaches to Glycemic Treatment, Standards of Care 2026
- FDA: Ozempic label and regulatory information
Editorial review note: reviewed for medical accuracy, source consistency, trial-specific kidney claims, medication caveats, and patient-safety framing before publication.